Pfizer Biopharmaceuticals Group
Hwang oversees a group that brought in nearly $40 billion in revenue in 2019, operates in 125 countries and includes 26,000 employees. She oversaw much of the work that it took to get the company’s COVID-19 vaccine manufactured, tested and to market quickly. That included jump-starting processes well ahead of time. “We began purchasing the materials we believed we would need—glass vials, tubing, raw materials—before we even knew which (vaccine) candidate would get approval,” Hwang told the Connecticut Business & Industry Association Economic Summit + Outlook 2021 in January.